References

Aouni, N., Linders, L., Robinson, D., Vandelaer, L., Wiezorek, J., Gupta, G., & Cavill, R. (2021). Interpreting multi-variate models with setPCA. *ArXiv:2111.09138 [Cs, q-Bio]*. http://arxiv.org/abs/2111.09138

Collinge, J., Gorham, M., Hudson, F., Kennedy, A., Keogh, G., Pal, S., Rossor, M., Rudge, P., Siddique, D., Spyer, M., Thomas, D., Walker, S., Webb, T., Wroe, S., & Darbyshire, J. (2009). Safety and efficacy of quinacrine in human prion disease (PRION-1 study): A patient-preference trial. *The Lancet. Neurology*, *8*(4), 334–344. https://doi.org/10.1016/S1474-4422(09)70049-3

Daehee Hwang, Inyoul Y Lee, Hyuntae Yoo, Nils Gehlenborg, Ji-Hoon Cho, Brianne Petritis, David Baxter, Rose Pitstick, Rebecca Young, Doug Spicer, Nathan D Price, John G Hohmann, Stephen J DeArmond, George A Carlson, & Leroy E Hood. (2009). A systems approach to prion disease. *Molecular Systems Biology*, *5*(1), 252. https://doi.org/10.1038/msb.2009.10

Di Fede, G., Catania, M., Atzori, C., Moda, F., Pasquali, C., Indaco, A., Grisoli, M., Zuffi, M., Guaita, M. C., Testi, R., Taraglio, S., Sessa, M., Gusmaroli, G., Spinelli, M., Salzano, G., Legname, G., Tarletti, R., Godi, L., Pocchiari, M., … Giaccone, G. (2019). Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene. *Acta Neuropathologica Communications*, *7*(1), 1. https://doi.org/10.1186/s40478-018-0656-4

Eckland, T. E., Shikiya, R. A., & Bartz, J. C. (2018). Independent amplification of co-infected long incubation period low conversion efficiency prion strains. *PLOS Pathogens*, *14*(10), e1007323. https://doi.org/10.1371/journal.ppat.1007323

Frost, H. R., Li, Z., & Moore, J. H. (2015). Principal component gene set enrichment (PCGSE). *BioData Mining*, *8*, 25. https://doi.org/10.1186/s13040-015-0059-z

Garske, T., & Ghani, A. C. (2010). Uncertainty in the Tail of the Variant Creutzfeldt-Jakob Disease Epidemic in the UK. *PLOS ONE*, *5*(12), e15626. https://doi.org/10.1371/journal.pone.0015626

Gogia, N., Chimata, A. V., Deshpande, P., Singh, A., & Singh, A. (2020). Hippo signaling: Bridging the gap between cancer and neurodegenerative disorders. *Neural Regeneration Research*, *16*(4), 643–652. https://doi.org/10.4103/1673-5374.295273

Gomez-Gutierrez, R., & Morales, R. (2020). The prion-like phenomenon in Alzheimer's disease: Evidence of pathology transmission in humans. *PLOS Pathogens*, *16*(10), e1009004. https://doi.org/10.1371/journal.ppat.1009004

Hargrave, P. A., & McDowell, J. H. (1993). Rhodopsin and Phototransduction. In M. Friedlander & M. Mueckler (Eds.), *International Review of Cytology* (Vol. 137, pp. 49–97). Academic Press. https://doi.org/10.1016/S0074-7696(08)62600-5

Hijazi, N., Kariv-Inbal, Z., Gasset, M., & Gabizon, R. (2005). PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. *The Journal of Biological Chemistry*, *280*(17), 17057–17061. https://doi.org/10.1074/jbc.M411314200

Holman, R. C., Belay, E. D., Christensen, K. Y., Maddox, R. A., Minino, A. M., Folkema, A. M., Haberling, D. L., Hammett, T. A., Kochanek, K. D., Sejvar, J. J., & Schonberger, L. B. (2010). Human Prion Diseases in the United States. *PLOS ONE*, *5*(1), e8521. https://doi.org/10.1371/journal.pone.0008521

Huang, J., Wu, S., Barrera, J., Matthews, K., & Pan, D. (2005). The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP. *Cell*, *122*(3), 421–434. https://doi.org/10.1016/j.cell.2005.06.007

Imran, M., & Mahmood, S. (2011). An overview of animal prion diseases. *Virology Journal*, *8*(1), 493. https://doi.org/10.1186/1743-422X-8-493

Jackson, D. A. (1993). Stopping Rules in Principal Components Analysis: A Comparison of Heuristical and Statistical Approaches. *Ecology*, *74*(8), 2204–2214. https://doi.org/10.2307/1939574

Jolliffe, I. T., & Cadima, J. (2016). Principal component analysis: A review and recent developments. *Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences*, *374*(2065), 20150202. https://doi.org/10.1098/rsta.2015.0202

Kanyongo, G. (2005). Determining The Correct Number Of Components To Extract From A Principal Components Analysis: A Monte Carlo Study Of The Accuracy Of The Scree Plot. *Journal of Modern Applied Statistical Methods*, *4*, 120–133. https://doi.org/10.22237/jmasm/1114906380

Kara, D. (2009). Evaluation of trace metal concentrations in some herbs and herbal teas by principal component analysis. *Food Chemistry*, *114*(1), 347–354. https://doi.org/10.1016/j.foodchem.2008.09.054

Lenahan, C., Sanghavi, R., Huang, L., & Zhang, J. H. (2020). Rhodopsin: A Potential Biomarker for Neurodegenerative Diseases. *Frontiers in Neuroscience*, *14*, 326. https://doi.org/10.3389/fnins.2020.00326

Liang, K.-H. (2013). 3—Transcriptomics. In K.-H. Liang (Ed.), *Bioinformatics for Biomedical Science and Clinical Applications* (pp. 49–82). Woodhead Publishing. https://doi.org/10.1533/9781908818232.49

Liu, A., Zhang, Y., Gehan, E., & Clarke, R. (2002). Block principal component analysis with application to gene microarray data classification. *Statistics in Medicine*, *21*(22), 3465–3474. https://doi.org/10.1002/sim.1263

Mao, W., Zaslavsky, E., Hartmann, B. M., Sealfon, S. C., & Chikina, M. (2019). Pathway-level information extractor (PLIER) for gene expression data. *Nature Methods*, *16*(7), 607–610. https://doi.org/10.1038/s41592-019-0456-1

McKintosh, E., Tabrizi, S. J., & Collinge, J. (2003). Prion diseases. *Journal of Neurovirology*, *9*(2), 183–193. https://doi.org/10.1080/13550280390194082

Mead, S. (2006). Prion disease genetics. *European Journal of Human Genetics*, *14*(3), 273–281. https://doi.org/10.1038/sj.ejhg.5201544

Melit Devassy, B., & George, S. (2020). Dimensionality reduction and visualisation of hyperspectral ink data using t-SNE. *Forensic Science International*, *311*, 110194. https://doi.org/10.1016/j.forsciint.2020.110194

Mubeen, S., Hoyt, C. T., Gemünd, A., Hofmann-Apitius, M., Fröhlich, H., & Domingo-Fernández, D. (2019). The Impact of Pathway Database Choice on Statistical Enrichment Analysis and

Predictive Modeling. *Frontiers in Genetics*, *10*, 1203. https://doi.org/10.3389/fgene.2019.01203

Porta, M., & Morabia, A. (2004). Editorial: Why Aren't We More Ahead? The Risk of Variant Creutzfeldt-Jakob Disease from Eating Bovine Spongiform Encephalopathy-Infected Foods: Still Undetermined. *European Journal of Epidemiology*, *19*(4), 287–289.

Prasad, K. N., & Bondy, S. C. (2018). Oxidative and Inflammatory Events in Prion Diseases: Can they Be Therapeutic Targets? *Current Aging Science*, *11*(4), 216–225. https://doi.org/10.2174/1874609812666190111100205

Rai, S., Singh, P., Steinbusch, H., Vamanu, E., Ashraf, G., & Singh, M. (2021). The Role of Vitamins in Neurodegenerative Disease: An Update. *Biomedicines*. https://doi.org/10.3390/biomedicines9101284

Reimand, J., Isser, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., Wadi, L., Meyer, M., Wong, J., Xu, C., Merico, D., & Bader, G. D. (2019). Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. *Nature Protocols*, *14*(2), 482–517. https://doi.org/10.1038/s41596-018-0103-9

Ringnér, M. (2008). What is principal component analysis? *Nature Biotechnology*, *26*(3), 303–304. https://doi.org/10.1038/nbt0308-303

Sahab, U., Md, & Shah, A., Md. (2018). *Handbook of Research on Critical Examinations of Neurodegenerative Disorders*. IGI Global.

Sahu, M. R., & Mondal, A. C. (2020). The emerging role of Hippo signaling in neurodegeneration. *Journal of Neuroscience Research*, *98*(5), 796–814. https://doi.org/10.1002/jnr.24551

Silva, J. L., Vieira, T. C. R. G., Gomes, M. P. B., Rangel, L. P., Scapin, S. M. N., & Cordeiro, Y. (2011). Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion. *Methods*, *53*(3), 306–317. https://doi.org/10.1016/j.ymeth.2010.12.002

Soto, C., & Satani, N. (2011). The intricate mechanisms of neurodegeneration in prion diseases. *Trends in Molecular Medicine*, *17*(1), 14–24. https://doi.org/10.1016/j.molmed.2010.09.001

Stafford, P. (2008). *Methods in Microarray Normalization*. CRC Press.

Todorov, H., Fournier, D., & Susanne, G. (2018). Principal components analysis: Theory and application to gene expression data analysis. *Genomics and Computational Biology*, *4*, 100041. https://doi.org/10.18547/gcb.2018.vol4.iss2.e100041

Tsuyuzaki, K., Sato, H., Sato, K., & Nikaido, I. (2020). Benchmarking principal component analysis for large-scale single-cell RNA-sequencing. *Genome Biology*, *21*(1), 9. https://doi.org/10.1186/s13059-019-1900-3

University of Edinburgh. (2015, August 4). *Brain infection study reveals how disease spreads from gut: Research could enable earlier detection of prion diseases*. ScienceDaily. https://www.sciencedaily.com/releases/2015/08/150804103448.htm

Vallabh, S. M., Minikel, E. V., Schreiber, S. L., & Lander, E. S. (2020). Towards a treatment for genetic prion disease: Trials and biomarkers. *The Lancet. Neurology*, *19*(4), 361–368. https://doi.org/10.1016/S1474-4422(19)30403-X

Verhaak, R. G., Staal, F. J., Valk, P. J., Lowenberg, B., Reinders, M. J., & de Ridder, D. (2006). The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. *BMC Bioinformatics*, *7*(1), 105. https://doi.org/10.1186/1471-2105-7-105

Wagner, F. (2015). *GO-PCA: An Unsupervised Method to Explore Biological Heterogeneity Based on Gene Expression and Prior Knowledge* (p. 018705). https://doi.org/10.1101/018705

Yang, D., Zhao, D., Shah, S. Z. A., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., Gao, H., Zhou, X., & Yang, L. (2020). Implications of gut microbiota dysbiosis and metabolic changes in prion disease. *Neurobiology of Disease*, *135*, 104704. https://doi.org/10.1016/j.nbd.2019.104704